April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LHBetaTAg Retinal Tumors
Author Affiliations & Notes
  • Samuel K. Houston
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Timothy G. Murray
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Christina L. Decatur
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Yolanda Pina
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Ludimila Cavalcante
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Theodore Lampidis
    Anatomy and Cell Biology, University of Miami, Miami, Florida
  • Footnotes
    Commercial Relationships  Samuel K. Houston, None; Timothy G. Murray, None; Christina L. Decatur, None; Yolanda Pina, None; Ludimila Cavalcante, None; Theodore Lampidis, None
  • Footnotes
    Support  NIH center grant R01 EY013629, R01 EY12651, and P30 EY014801; by the American Cancer Society, Sylvester Comprehensive Cancer Center; and by an unrestricted grant to the University of Miami from Resear
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2487. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samuel K. Houston, Timothy G. Murray, Christina L. Decatur, Yolanda Pina, Ludimila Cavalcante, Theodore Lampidis; Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LHBetaTAg Retinal Tumors. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2487.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The aim of the current study is to assess the impact of 2-fluorodeoxy-D-glucose (2-FDG) on tumor burden and hypoxia in the LHBETATAG retinal tumors.

Methods: : The study protocol was approved by the University of Miami Institutional Animal Care and Use Review Board Committee and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 17-week old (n=54) LHBETATAG transgenic mice were treated with 2-fluorodeoxy-D-glucose or saline control. These animals received one of three different treatments: (1) one injection of 2-FDG and sacrificed at one day post-treatment, (2) one injection of 2-FDG and sacrificed at one week post-treatment, or (3) 6 injections of 2-FDG (twice weekly injections repeated for three weeks) and sacrificed at one day post-last injection. At the time of enucleation, eye samples were snap frozen and analyzed for tumor burden and hypoxia using immunohistochemical techniques. Average densities of the different groups were statistically analyzed using ANOVA analysis. Results were considered significant if p≤ 0.05.

Results: : There was no apparent toxicity associated with 2-fluorodeoxy-D-glucose treatment. There was a significant reduction in tumor burden following treatment with 2-FDG at 1 day (86%) and 3 weeks (63%) post-treatment (p≤0.05). There was no reduction of tumor burden observed when mice were treated with 1 injection and eyes harvested at 1 week post-treatment (2%, p=0.0640). There was a significant reduction in hypoxic areas following treatment with 2-FDG at 1 day (100%) and 3 weeks (75%) post-treatment (p≤0.05).

Conclusions: : 2-fluorodeoxy-D-glucose (2-FDG) significantly reduces tumor burden and tumor hypoxia following a single injection, with continued efficacy following repeated injections for 3 weeks. 2-FDG treatment is efficacious in murine retinoblastoma tumors and may enhance tumor control when combined with other therapies. 2-FDG appears to target hypoxic cells, a population that has been resistant to chemotherapy and radiation. Of interest, 2-FDG is readily available and commonly used in medical imaging and has minimal known toxicities.

Keywords: retinoblastoma • hypoxia • metabolism 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×